Andrés Gómez‐De León

ORCID: 0000-0001-6904-9345 · 1 paper in corpus
article 2017
·doi:10.1016/j.clml.2017.11.007

BackgroundAllogeneic stem cell transplantation (ASCT) represents the only option with a potential cure rate of 30% to 50% in myelodysplastic syndrome (MDS); however, < 5% of patients are optimal candidates for this management. Therapeutic o…